Is This The Turning Point for Inovio?

It seems such a long time ago that Inovio Pharmaceuticals (NASDAQ: INO) was considered one of the leaders in the hunt for a COVID-19 vaccine -- but the biotech was left in the dust by peers and many investors have given up on the stock. In the past 12 months, shares of Inovio are down 45% even as the broader market took off.

However, the company hasn't given up hope to develop an effective vaccine for the coronavirus -- and thanks to recent regulatory developments, it could be a bit closer to this goal. Let's see whether the company is finally ready to turn things around.

Source Fool.com